BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 1731514)

  • 1. Hepatic toxicity of unmodified and time-release preparations of niacin.
    Rader JI; Calvert RJ; Hathcock JN
    Am J Med; 1992 Jan; 92(1):77-81. PubMed ID: 1731514
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rechallenge with crystalline niacin after drug-induced hepatitis from sustained-release niacin.
    Henkin Y; Johnson KC; Segrest JP
    JAMA; 1990 Jul; 264(2):241-3. PubMed ID: 2355446
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hepatotoxicity associated with sustained-release niacin.
    Dalton TA; Berry RS
    Am J Med; 1992 Jul; 93(1):102-4. PubMed ID: 1626557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Fulminant hepatic failure after ingestion of sustained-release nicotinic acid.
    Mullin GE; Greenson JK; Mitchell MC
    Ann Intern Med; 1989 Aug; 111(3):253-5. PubMed ID: 2665592
    [No Abstract]   [Full Text] [Related]  

  • 5. Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin.
    Etchason JA; Miller TD; Squires RW; Allison TG; Gau GT; Marttila JK; Kottke BA
    Mayo Clin Proc; 1991 Jan; 66(1):23-8. PubMed ID: 1988755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transient focal hepatic defects related to sustained-release niacin.
    Lawrence SP
    J Clin Gastroenterol; 1993 Apr; 16(3):234-6. PubMed ID: 8505497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute hepatic failure associated with the use of low-dose sustained-release niacin.
    Hodis HN
    JAMA; 1990 Jul; 264(2):181. PubMed ID: 2355439
    [No Abstract]   [Full Text] [Related]  

  • 8. Comment: adverse-effect profile of sustained-release niacin.
    Jungnickel PW; Maloley PA
    DICP; 1991 Sep; 25(9):1014-5. PubMed ID: 1949965
    [No Abstract]   [Full Text] [Related]  

  • 9. Safety and side effects of sustained-release niacin.
    Lavie CJ; Milani RV
    JAMA; 1994 Aug; 272(7):513-4; author reply 514-5. PubMed ID: 8046796
    [No Abstract]   [Full Text] [Related]  

  • 10. Hepatitis caused by low-dose sustained-release niacin.
    Schwenk TL; Fisher M
    J Am Board Fam Pract; 1994; 7(3):242-4. PubMed ID: 8059629
    [No Abstract]   [Full Text] [Related]  

  • 11. Niacin and hepatic failure.
    Knopp RH
    Ann Intern Med; 1989 Nov; 111(9):769. PubMed ID: 2802441
    [No Abstract]   [Full Text] [Related]  

  • 12. Clinical profiles of plain versus sustained-release niacin (Niaspan) and the physiologic rationale for nighttime dosing.
    Knopp RH
    Am J Cardiol; 1998 Dec; 82(12A):24U-28U; discussion 39U-41U. PubMed ID: 9915659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The bioavailability of sustained release nicotinic acid formulations.
    Neuvonen PJ; Roivas L; Laine K; Sundholm O
    Br J Clin Pharmacol; 1991 Oct; 32(4):473-6. PubMed ID: 1958442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety and tolerability of extended-release niacin with laropiprant.
    Yadav R; Kwok S; Ammori BJ; Issa B; Soran H
    Expert Opin Drug Saf; 2012 Jan; 11(1):151-9. PubMed ID: 22133050
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Niacin-induced hepatotoxicity: unusual presentations.
    Coppola A; Brady PG; Nord HJ
    South Med J; 1994 Jan; 87(1):30-2. PubMed ID: 8284714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of an extended-release niacin (Niaspan): a long-term study.
    Capuzzi DM; Guyton JR; Morgan JM; Goldberg AC; Kreisberg RA; Brusco OA; Brody J
    Am J Cardiol; 1998 Dec; 82(12A):74U-81U; discussion 85U-86U. PubMed ID: 9915666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adverse effects of sustained-release niacin.
    Knapp TR; Middleton RK
    DICP; 1991 Mar; 25(3):253-4. PubMed ID: 2028632
    [No Abstract]   [Full Text] [Related]  

  • 18. Pharmacoepidemiology of niacin.
    Jungnickel PW; Maloley PA
    Ann Intern Med; 1995 Mar; 122(5):392-3. PubMed ID: 7847654
    [No Abstract]   [Full Text] [Related]  

  • 19. Alterations in thyroid and hepatic function tests associated with preparations of sustained-release niacin.
    Drinka PJ
    Mayo Clin Proc; 1992 Dec; 67(12):1206. PubMed ID: 1469935
    [No Abstract]   [Full Text] [Related]  

  • 20. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.
    Morgan JM; Capuzzi DM; Guyton JR
    Am J Cardiol; 1998 Dec; 82(12A):29U-34U; discussion 39U-41U. PubMed ID: 9915660
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.